Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | Universidade de São Paulo (USP) | - |
Autor(es): dc.contributor | Barretos Cancer Hospital | - |
Autor(es): dc.contributor | Vrije Universiteit Brussel | - |
Autor(es): dc.contributor | University of Minho | - |
Autor(es): dc.contributor | 3B's - PT Government Associate Laboratory | - |
Autor(es): dc.creator | Romualdo, Guilherme Ribeiro [UNESP] | - |
Autor(es): dc.creator | Prata, Gabriel Bacil [UNESP] | - |
Autor(es): dc.creator | da Silva, Tereza Cristina | - |
Autor(es): dc.creator | Evangelista, Adriane Feijó | - |
Autor(es): dc.creator | Reis, Rui Manuel | - |
Autor(es): dc.creator | Vinken, Mathieu | - |
Autor(es): dc.creator | Moreno, Fernando Salvador | - |
Autor(es): dc.creator | Cogliati, Bruno | - |
Autor(es): dc.creator | Barbisan, Luís Fernando [UNESP] | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:32:22Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:32:22Z | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2020-10-31 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1016/j.jnutbio.2020.108479 | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/201020 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/201020 | - |
Descrição: dc.description | Aberrant microRNA expression implicates on hepatocellular carcinoma (HCC) development. Conversely, coffee consumption reduces by ~40% the risk for fibrosis/cirrhosis and HCC, while decaffeinated coffee does not. It is currently unknown whether these protective effects are related to caffeine (CAF), or to its combination with other common and/or highly bioavailable coffee compounds, such as trigonelline (TRI) and chlorogenic acid (CGA). We evaluated whether CAF individually or combined with TRI and/or CGA alleviates fibrosis-associated hepatocarcinogenesis, examining the involvement of miRNA profile modulation. Then, male C3H/HeJ mice were submitted to a diethylnitrosamine/carbon tetrachloride-induced model. Animals received CAF (50 mg/kg), CAF+TRI (50 and 25 mg/kg), CAF+CGA (50 and 25 mg/kg) or CAF+TRI+CGA (50, 25 and 25 mg/kg), intragastrically, 5×/week, for 10 weeks. Only CAF+TRI+CGA combination reduced the incidence, number and proliferation (Ki-67) of hepatocellular preneoplastic foci while enhanced apoptosis (cleaved caspase-3) in adjacent parenchyma. CAF+TRI+CGA treatment also decreased hepatic oxidative stress and enhanced the antioxidant Nrf2 axis. CAF+TRI+CGA had the most pronounced effects on decreasing hepatic pro-inflammatory IL-17 and NFκB, contributing to reduce CD68-positive macrophage number, stellate cell activation, and collagen deposition. In agreement, CAF+TRI+CGA upregulated tumor suppressors miR-144-3p, miR-376a-3p and antifibrotic miR-15b-5p, frequently deregulated in human HCC. CAF+TRI+CGA reduced the hepatic protein levels of pro-proliferative EGFR (miR-144-3p target), antiapoptotic Bcl-2 family members (miR-15b-5p targets), and the number of PCNA (miR-376a-3p target) positive hepatocytes in preneoplastic foci. Our results suggest that the combination of most common and highly bioavailable coffee compounds, rather than CAF individually, attenuates fibrosis-associated hepatocarcinogenesis by modulating miRNA expression profile. | - |
Descrição: dc.description | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | - |
Descrição: dc.description | Department of Pathology Botucatu Medical School São Paulo State University (UNESP) | - |
Descrição: dc.description | Department of Structural and Functional Biology Biosciences Institute São Paulo State University (UNESP) | - |
Descrição: dc.description | Department of Pathology School of Veterinary Medicine and Animal Science University of São Paulo (USP) | - |
Descrição: dc.description | Molecular Oncology Research Center Barretos Cancer Hospital | - |
Descrição: dc.description | Department of In Vitro Toxicology and Dermato-Cosmetology Faculty of Medicine and Pharmacy Vrije Universiteit Brussel | - |
Descrição: dc.description | Department of Food and Experimental Nutrition Faculty of Pharmaceutical Sciences University of São Paulo (USP) | - |
Descrição: dc.description | Life and Health Sciences Research Institute (ICVS) School of Medicine University of Minho | - |
Descrição: dc.description | 3B's - PT Government Associate Laboratory | - |
Descrição: dc.description | Department of Pathology Botucatu Medical School São Paulo State University (UNESP) | - |
Descrição: dc.description | Department of Structural and Functional Biology Biosciences Institute São Paulo State University (UNESP) | - |
Descrição: dc.description | FAPESP: #2016/12015–0 | - |
Descrição: dc.description | FAPESP: #2016/14420–0 | - |
Descrição: dc.description | FAPESP: #2017/16596–0 | - |
Idioma: dc.language | en | - |
Relação: dc.relation | Journal of Nutritional Biochemistry | - |
???dc.source???: dc.source | Scopus | - |
Palavras-chave: dc.subject | Caffeine | - |
Palavras-chave: dc.subject | Chlorogenic acid | - |
Palavras-chave: dc.subject | Hepatocarcinogenesis | - |
Palavras-chave: dc.subject | Liver fibrosis | - |
Palavras-chave: dc.subject | miRNA | - |
Palavras-chave: dc.subject | Trigonelline | - |
Título: dc.title | The combination of coffee compounds attenuates early fibrosis-associated hepatocarcinogenesis in mice: involvement of miRNA profile modulation | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: